Evidence map›Paper›PMID 30077399›Full record

ArticleEuropean urology2018

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.

Eleanor L Watts, Paul N Appleby, Aurora Perez-Cornago, H Bas Bueno-de-Mesquita, June M Chan, Chu Chen, Barbara A Cohn, Michael B Cook, Leon Flicker, Neal D Freedman and 35 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 6 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 6 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 12 countries.

Eleanor L WattsCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: ellie.watts@ndph.ox.ac.uk.
Paul N ApplebyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Aurora Perez-CornagoCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
H Bas Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands; Department of Epidemiology and Biostatistics, Imperial College London, London, UK; Department of Social & Preventive Medicine, University of Malaya, Kuala Lumpur, Malaysia.
June M ChanDepartment of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA; Department of Urology, University of California-San Francisco, San Francisco, CA, USA.
Chu ChenPublic Health Sciences Division, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Barbara A CohnChild Health and Development Studies, Public Health Institute, Berkeley, CA, USA.
Michael B CookDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
Leon FlickerSchool of Medicine, University of Western Australia, Perth, Western Australia, Australia; Western Australian Centre for Health and Ageing, Centre for Medical Research, University of Western Australia, Perth, Western Australia, Australia.
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Bethesda, MD, USA.
Graham G GilesCancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Edward GiovannucciDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; The Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Randi E GislefossCancer Registry of Norway, Institute for Epidemiological Cancer Research, Oslo, Norway.
Graeme J HankeySchool of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
Paul KnektNational Institute for Health and Welfare, Helsinki, Finland.
Laurence N KolonelUniversity of Hawaii Cancer Center, Honolulu, HI, USA.
Tatsuhiko KuboDepartment of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Kitakyushu, Japan.
Loïc Le MarchandUniversity of Hawaii Cancer Center, Honolulu, HI, USA.
Robert N LubenStrangeways Research Laboratory, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Tapio LuostarinenFinnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland.
Satu MännistöDepartment of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
E Jeffrey MetterDepartment of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA.
Kazuya MikamiDepartment of Urology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.
Roger L MilneCancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Kotaro OzasaDepartment of Epidemiology, Radiation Effects Research Foundation, Hiroshima, Japan.
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Harri RissanenNational Institute for Health and Welfare, Helsinki, Finland.
Norie SawadaEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Meir StampferDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; The Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Frank Z StanczykDivision of Reproductive Endocrinology and Infertility, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Pär StattinDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Akiko TamakoshiDepartment of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ian M ThompsonCancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, TX, USA.
Konstantinos K TsilidisDepartment of Epidemiology and Biostatistics, Imperial College London, London, UK; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Shoichiro TsuganeEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Giske UrsinCancer Registry of Norway, Institute for Epidemiological Cancer Research, Oslo, Norway; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
Lars VattenDepartment of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Noel S WeissDepartment of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
Bu B YeapSchool of Medicine, University of Western Australia, Perth, Western Australia, Australia; Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Naomi E AllenClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
University of Oxford · GBFinnish Institute for Health and Welfare · FIUniversity of Western Australia · AUCancer Registry of Norway · NODivision of Cancer Epidemiology and GeneticsFred Hutch Cancer Center · USHarvard University · USUniversity of Southern California · USCancer Center of Hawaii · USCancer Council Victoria · AUFinnish Cancer Registry · FIGerman Cancer Research Center · DEGobierno del Principado de Asturias · ESImperial College London · GBJohns Hopkins University · USKyoto Prefectural University of Medicine · JPNorwegian University of Science and Technology · NOPublic Health Institute · USRadiation Effects Research Foundation · JPUniversity Medical Center Utrecht · NL

Funding

SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
Cancer Research UK 16491Cancer Research UK 19170Cancer Research UK C8221/A19170Cancer Research UK C8221/A20986Medical Research Council G1000143NCI NIH HHS HHSN261201000034CNCI NIH HHS HHSN261201000035CNCI NIH HHS HHSN261201000140CNCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167462NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883NICHD NIH HHS HHSN275201100020C
6 · The paper itself

Abstract

backgroundExperimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting.

objectiveTo examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer. DESIGN, SETTING, AND

participantsAnalysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration. RESULTS AND LIMITATIONS: Men in the lowest tenth of free testosterone concentration had a lower risk of overall prostate cancer (OR=0.77, 95% confidence interval [CI] 0.69-0.86; p<0.001) compared with men with higher concentrations (2nd-10th tenths of the distribution). Heterogeneity was present by tumour grade (p

conclusionsMen with low circulating free testosterone may have a lower risk of overall prostate cancer; this may be due to a direct biological effect, or detection bias. Further research is needed to explore the apparent differential association by tumour grade. PATIENT SUMMARY: In this study, we looked at circulating testosterone levels and risk of developing prostate cancer, finding that men with low testosterone had a lower risk of prostate cancer.

Indexed as

AdultAgedBiomarkersCase-Control StudiesDown-RegulationHumansMaleMiddle AgedNeoplasm GradingProspective StudiesProstatic NeoplasmsProtective FactorsRisk AssessmentRisk FactorsTestosteroneTime FactorsBiomarkersTestosteroneAndrogensEpidemiologyPooled analysisProspective studiesProstate cancerSex hormonesTestosterone

Identifiers

PMID30077399
PMCPMC6195673
OpenAlexW2886173583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.